These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21824646)

  • 1. Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas.
    Harris LF; Castro-López V; Jenkins PV; O'Donnell JS; Killard AJ
    Thromb Res; 2011 Dec; 128(6):e125-9. PubMed ID: 21824646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.
    Harris LF; O'Brien A; Castro-López V; O'Donnell JS; Killard AJ
    Thromb Res; 2011 Dec; 128(6):e166-70. PubMed ID: 21872908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins.
    Harris LF; Castro-López V; Hammadi N; O'Donnell JS; Killard AJ
    Talanta; 2010 Jun; 81(4-5):1725-30. PubMed ID: 20441964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
    Castro-López V; Harris LF; O'Donnell JS; Killard AJ
    Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
    Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
    Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
    Cvirn G; Wagner T; Juergens G; Koestenberger M
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of thromboelastography in monitoring low molecular weight heparin therapy in the coronary care unit.
    White H; Sosnowski K; Bird R; Jones M; Solano C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):304-10. PubMed ID: 22473047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of plasma anti-Xa activity in low-molecular-weight heparin monitoring.
    Rojnuckarin P; Akkawat B; Juntiang J
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):313-7. PubMed ID: 19520682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy.
    Harris LF; Rainey P; Castro-López V; O'Donnell JS; Killard AJ
    Analyst; 2013 Sep; 138(17):4769-76. PubMed ID: 23666610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.